Talaris is Rapidly Expanding as it Speeds Toward a First BLA

On the heels of a successful $150 million IPO in May, and with promising clinical data in hand, Talaris Therapeutics is experiencing rapid growth. The Louisville, Kentucky-based biopharma company, a member of BioSpace’s NextGen Bio ‘Class of 2020’, is developing a one-time cell therapy that could enable kidney transplant patients to ditch their immunosuppression medications.